Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Video

Updated: Jan 14, 2026

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

Driver mutations in melanoma: lessons learned from bench-to-bedside studies.

Janice M Mehnert¹, Harriet M Kluger

¹The Cancer Institute of New Jersey, 195 Little Albany Street Rm 5543, New Brunswick, NJ 08903, USA. mehnerja@umdnj.edu

Current Oncology Reports

|June 23, 2012

Summary

Molecular insights into melanoma have led to targeted therapies, particularly for BRAF(V600E) mutations. This review covers key mutations and emerging targets in melanoma, discussing bench-to-bedside research and future strategies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Development of [<sup>111</sup>In]In-CHX-A″-DTPA-αCD68 for ImmunoSPECT to Image Murine Macrophages.

Molecular pharmaceutics·2026

Same author

Immune checkpoint inhibitor therapy after tumor-infiltrating lymphocytes in unresectable melanoma.

Journal for immunotherapy of cancer·2026

Same author

Advances in Cancer Immunotherapy for Solid Tumors.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026

Same author

Intismeran Autogene Plus Pembrolizumab Versus Pembrolizumab Alone in High-Risk Resected Melanoma: 5-Year Update of the Randomized Phase IIb KEYNOTE-942 Study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Same author

Systemic Therapies for the Treatment of Cutaneous Malignancies in Solid Organ Transplant Recipients.

Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]·2026

Same author

Ex Vivo Expansion of Melanoma Tumor-Infiltrating Lymphocytes Leads to a Dominant Exhausted T-cell Population with a Lack of Memory Markers.

Cancer immunology research·2026

Area of Science:

Oncology
Genetics
Molecular Biology

Background:

Somatic driver mutations are crucial for classifying melanoma.
Understanding melanoma's molecular biology has revolutionized metastatic treatment.
BRAF(V600E) inhibitors represent a major therapeutic advance.

Purpose of the Study:

To review key mutations in melanoma development.
To discuss emerging mutations in cutaneous and uveal melanoma.
To summarize research collaborations and therapeutic strategies.

Main Methods:

Review of scientific literature on melanoma driver mutations.
Analysis of molecular classifications and therapeutic targets.
Summary of bench-to-bedside research in melanoma.

More Related Videos

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Published on: June 7, 2019

A Melanoma Patient-Derived Xenograft Model

A Melanoma Patient-Derived Xenograft Model

Published on: May 20, 2019

Related Experiment Videos

Last Updated: Jan 14, 2026

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Published on: June 7, 2019

A Melanoma Patient-Derived Xenograft Model

A Melanoma Patient-Derived Xenograft Model

Published on: May 20, 2019

Main Results:

Identification of critical mutations including BRAF, PTEN, NRAS, ckit, and p16.
Emerging mutations in cutaneous and uveal melanoma are highlighted.
Bench-to-bedside collaborations have driven therapeutic discoveries.

Conclusions:

Targeting specific driver mutations offers personalized therapeutic strategies for melanoma patients.
Continued research into melanoma's molecular landscape is vital for advancing treatment.
Understanding genetic alterations is key to developing effective melanoma therapies.